DSM Food Specialties retains the dairy portion of Lafti business through a licence agreement, reflecting the company’s strategy to concentrate on food and beverage probiotic applications.
Lafti probiotics are suitable for a range of dietary supplement formats, such as hard gel capsules, tablets or soft gels. Their high concentration, survival and stability properties enable a variety of formulations: alone or in associated with prebiotics, minerals, vitamin, or other healthy ingredients, said the company.
Lafti range of documented probiotics comprises of three strains: Lactobacillus acidophilus Lafti L10 (L10), Lactobacillus casei Lafti L26 (L26), Bifidobacterium animalis lactis Lafti B94 (B94).
Institut Rosell-Lallemand claimed that Lafti represents an asset to its existing portfolio of probiotics targeting specific health segments such as gut health, immunology, women’s and children’s health.
The company said that Lafti probiotic strains have been developed, documented and marketed in both dietary supplements and dairy applications by DSM as a result of a scientific research program which covers benefits from different areas of immunity, healthy digestion and vitality level.
Olivier Clech, vice president of Lallemand Human and Animal Nutrition, said: “DSM Lafti range of probiotic strains benefits from an excellent reputation and is endorsed by strong scientific and clinical back-up. Over the years, DSM has developed major partnerships with key players of the health and food industry as well as recognized scientific opinion leaders.
“The quality and reputation of these strains fits perfectly in our own probiotic portfolio, complementing it with new species, such as Bifidobacterium animalis lactis and offering novel areas of applications such as sport health and athletes recovery.”